Elad Asher: Higher IPF Is Associated with Adverse Outcomes in ICCU
Elad Asher, Head ICCU at Shaare Zedek Medical Center, Jerusalem, shared a post on X about a recent article he and his colleagues co-authored, published in Thrombosis and Haemostasis, adding:
“Pleased to share our new paper in Thrombosis and Haemostasis.
In an unselected ICCU cohort, higher immature platelet fraction was independently associated with adverse outcomes, supporting IPF as a readily available risk marker.”
Title: Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit
Authors: Elad Asher, Louay Taha, Mohammad Karmi, Akiva Brin, Pierre Sabouret, Mamas A. Mamas, Noam Fink, Ari Naimark, Amjad Abu-Salman, Michael Glikson
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters